Vetr lowered shares of CVS Health (NYSE:CVS) from a hold rating to a sell rating in a research report sent to investors on Tuesday. They currently have $76.66 target price on the pharmacy operator’s stock.
A number of other brokerages also recently issued reports on CVS. Royal Bank of Canada assumed coverage on CVS Health in a report on Tuesday, September 19th. They set an outperform rating and a $95.00 price target for the company. Leerink Swann lifted their price target on CVS Health from $82.00 to $90.00 and gave the stock an outperform rating in a report on Monday, January 8th. Oppenheimer reaffirmed a buy rating and set a $95.00 price target on shares of CVS Health in a report on Monday, October 9th. Mizuho set a $90.00 price target on CVS Health and gave the stock a buy rating in a report on Tuesday, October 24th. Finally, Morgan Stanley raised CVS Health from an equal weight rating to an overweight rating and set a $88.00 price target for the company in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $86.63.
Shares of CVS Health (NYSE CVS) traded up $0.66 during midday trading on Tuesday, reaching $79.44. The company’s stock had a trading volume of 8,437,101 shares, compared to its average volume of 8,990,430. The stock has a market cap of $80,410.00, a P/E ratio of 16.41, a price-to-earnings-growth ratio of 1.25 and a beta of 0.90. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.72.
CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. CVS Health’s revenue for the quarter was up 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.64 EPS. equities analysts anticipate that CVS Health will post 5.89 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 2.52%. The ex-dividend date is Tuesday, January 23rd. CVS Health’s payout ratio is currently 41.32%.
In other news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total value of $2,208,375.00. Following the completion of the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.61% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the stock. Fieldpoint Private Securities LLC increased its position in CVS Health by 333.3% in the 2nd quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 1,000 shares during the period. Wealthcare Advisory Partners LLC increased its position in CVS Health by 330.3% in the 3rd quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock valued at $105,000 after acquiring an additional 991 shares during the period. Arcadia Investment Management Corp MI increased its position in CVS Health by 119.6% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the period. MPS Loria Financial Planners LLC acquired a new position in CVS Health during the 2nd quarter worth approximately $119,000. Finally, Gemmer Asset Management LLC increased its position in CVS Health by 15.3% during the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock worth $121,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 81.69% of the company’s stock.
WARNING: “CVS Health (CVS) Lowered to Sell at Vetr” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/17/cvs-health-cvs-lowered-to-sell-at-vetr.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.